Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

(JAMA Network Open) Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Mercy Health — Lourdes Hospital has officially restarted its structural heart program after Dr. Shankho Ganguli performed the ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic ...